Experimental drug for advanced prostate cancer shows promiseApril 15th, 2010 - 4:01 pm ICT by ANI
London, April 15 (ANI): A new study suggests that an experimental drug could be a weapon for doctors in the battle against an aggressive form of advanced prostate cancer.
The research, led by investigators at Memorial Sloan-Kettering Cancer Center, has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its poor prognosis and limited treatment options.
According to the findings of the Phase 1-2 study, MDV3100 not only shrank patients’ tumours, but also reduced serum levels of the tumour marker prostate-specific antigen (PSA), stabilized disease that had spread to soft tissues and the bone, and reduced the number of circulating tumour cells in the blood.
“We were encouraged to see anti-tumour activity in men whose disease had spread to other parts of the body after either becoming resistant to previous hormone treatments or progressing following chemotherapy,” said the study’s lead author Howard Scher, Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering.
“These findings strengthen the drug’s potential to change the outlook for a group of patients who currently have limited effective treatment options from which to choose,” Scher added.
The study appears early online and in an upcoming edition of The Lancet. (ANI)
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
- Novel drug shows promise in treating drug-resistant prostate cancer - Apr 08, 2009
- Genomic analysis of prostate cancer unveiled - Jun 26, 2010
- Australian scientists identify new way to treat prostate cancer - Feb 26, 2010
- CT scan more effective in parallel breast and bone cancer detection - Sep 06, 2010
- 'Spectacular' treatment for skin cancer developed - Sep 24, 2009
- Tumours capable of making their own blood vessels: Study - Nov 22, 2010
- Silicone implants 'more satisfactory' than saline implants: Study - Nov 08, 2010
- Why some women suffer breast cancer relapses - Oct 05, 2009
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Human trials for single injection cancer cure to begin - Mar 07, 2010
- Change in PSA level poor predictor of prostate cancer - Feb 25, 2011
- 'Self-seeding' of cancer cells may pave way for new therapies - Dec 25, 2009
- Acupuncture eases side effects and symptoms of some cancers - Sep 06, 2010
- Breast reconstruction helps women regain sexual wellness - Oct 24, 2011
Tags: chemotherapy, experimental drug, hormone treatments, howard scher, kettering cancer center, lancet, memorial sloan kettering, memorial sloan kettering cancer center, oncology service, poor prognosis, prostate cancer, prostate specific antigen, serum levels, sloan kettering cancer, sloan kettering cancer center, soft tissues, treatment options, tumour cells, tumour marker, tumours